Neutralisation hierarchy of SARS-CoV-2 Variants of Concern using standardised, quantitative neutralisation assays reveals a correlation with disease severity; towards deciphering protective antibody thresholds
View ORCID ProfileDiego Cantoni, View ORCID ProfileMartin Mayora-Neto, Angalee Nadesalingham, View ORCID ProfileDavid A. Wells, View ORCID ProfileGeorge W. Carnell, Luis Ohlendorf, Matteo Ferarri, Phil Palmer, Andrew C.Y. Chan, Peter Smith, View ORCID ProfileEmma M. Bentley, View ORCID ProfileSebastian Einhauser, Ralf Wagner, Mark Page, Gianmarco Raddi, View ORCID ProfileHelen Baxendale, Javier Castillo-Olivares, View ORCID ProfileJonathan Heeney, View ORCID ProfileNigel Temperton on behalf of the HICC Consortium
doi: https://doi.org/10.1101/2021.05.24.21257729
Diego Cantoni
1Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham, United Kingdom
Martin Mayora-Neto
1Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham, United Kingdom
Angalee Nadesalingham
2Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
David A. Wells
2Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
3DIOSynVax, University of Cambridge, Madingley Road, CB3-0ES, Cambridge
George W. Carnell
2Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
Luis Ohlendorf
2Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
Matteo Ferarri
3DIOSynVax, University of Cambridge, Madingley Road, CB3-0ES, Cambridge
Phil Palmer
2Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
Andrew C.Y. Chan
2Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
Peter Smith
2Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
Emma M. Bentley
5Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany
Sebastian Einhauser
4Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
Ralf Wagner
4Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
5Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany
Mark Page
6Division of Virology, National Institute for Biological Standards and Control, Potters Bar, UK
Gianmarco Raddi
7Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK
Helen Baxendale
7Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK
Javier Castillo-Olivares
2Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
Jonathan Heeney
2Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
3DIOSynVax, University of Cambridge, Madingley Road, CB3-0ES, Cambridge
Nigel Temperton
1Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham, United Kingdom
Article usage
Posted August 20, 2021.
Neutralisation hierarchy of SARS-CoV-2 Variants of Concern using standardised, quantitative neutralisation assays reveals a correlation with disease severity; towards deciphering protective antibody thresholds
Diego Cantoni, Martin Mayora-Neto, Angalee Nadesalingham, David A. Wells, George W. Carnell, Luis Ohlendorf, Matteo Ferarri, Phil Palmer, Andrew C.Y. Chan, Peter Smith, Emma M. Bentley, Sebastian Einhauser, Ralf Wagner, Mark Page, Gianmarco Raddi, Helen Baxendale, Javier Castillo-Olivares, Jonathan Heeney, Nigel Temperton
medRxiv 2021.05.24.21257729; doi: https://doi.org/10.1101/2021.05.24.21257729
Neutralisation hierarchy of SARS-CoV-2 Variants of Concern using standardised, quantitative neutralisation assays reveals a correlation with disease severity; towards deciphering protective antibody thresholds
Diego Cantoni, Martin Mayora-Neto, Angalee Nadesalingham, David A. Wells, George W. Carnell, Luis Ohlendorf, Matteo Ferarri, Phil Palmer, Andrew C.Y. Chan, Peter Smith, Emma M. Bentley, Sebastian Einhauser, Ralf Wagner, Mark Page, Gianmarco Raddi, Helen Baxendale, Javier Castillo-Olivares, Jonathan Heeney, Nigel Temperton
medRxiv 2021.05.24.21257729; doi: https://doi.org/10.1101/2021.05.24.21257729
Subject Area
Subject Areas
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2600)
- Dermatology (218)
- Emergency Medicine (391)
- Epidemiology (12135)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4031)
- Geriatric Medicine (380)
- Health Economics (670)
- Health Informatics (2605)
- Health Policy (994)
- Hematology (359)
- HIV/AIDS (832)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3797)
- Nursing (208)
- Nutrition (564)
- Oncology (1989)
- Ophthalmology (576)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (249)
- Palliative Medicine (72)
- Pathology (470)
- Pediatrics (1098)
- Primary Care Research (443)
- Public and Global Health (6470)
- Radiology and Imaging (1379)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (337)
- Surgery (438)
- Toxicology (51)
- Transplantation (185)
- Urology (165)